Targeting elevated DPP-4 levels, the inhibitor reduces pathological calcification in blood vessels and valves.
Isolated cynomolgus monkey interferon omega nucleic acids enable functional protein expression, resolving safety assessment gaps in non-human primate models.
A Bluetongue virus vaccine strain uses reverse genetics to introduce mutations into essential genes for controlled replication.
Omitting hypertonic resealing after hypotonic encapsulation increases cargo-loaded red cell extracellular vesicle yield and immune uptake.
GFAT-modulating agents restore Axin pathway function to treat tumors with defective beta-catenin signaling.
Specific single nucleotide polymorphisms within the PKC-β1 gene identify genetic predisposition to diabetic kidney complications.
Nucleases introduce anti-HIV transgenes into stem cells via homology-directed repair to create resistant immune populations.
Intracellular PEBLs block CD2 surface expression, preventing fratricide and graft-versus-host disease while maintaining therapeutic consistency.
A microRNA-based diagnostic panel overcomes the limited correlation of traditional bone mineral density measurements with actual fracture risk.
An adenovirus-PPE complex reduces hepatotoxicity by coating the viral surface with PEGylated dendrimers and Erbitux antibodies.
Let-7 microRNAs mature fetal cardiomyocytes to an adult phenotype, resolving the limitation of inaccurate disease modeling.
Engineered promoters restrict gamma-sarcoglycan production to skeletal muscles, preventing cardiac toxicity while treating muscular dystrophy.
Replacing qPCR with disposable fluorescent probes reduces labor intensity and cost while maintaining detection accuracy for tissue injury assessment.
Chemical modification of deoxyuridine residues with hydrophobic groups enhances nucleolin binding affinity in G-rich oligonucleotide aptamers.
Helper-dependent adenoviral vectors deliver proteoglycan 4 genes to sustain cartilage health, replacing frequent injections with long-term expression.
Anti-OX40 agonist antibodies resolve incomplete treatment responses by boosting effector function while inhibiting regulatory suppression.